

James R Berenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7941163/publications.pdf>

Version: 2024-02-01

146
papers

10,994
citations

66234

42
h-index

30010

103
g-index

147
all docs

147
docs citations

147
times ranked

8730
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination. <i>Clinical Infection in Practice</i> , 2022, 13, 100130.	0.2	11
2	Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. <i>Hematological Oncology</i> , 2022, 40, 243-248.	0.8	4
3	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 523-534.	0.2	3
4	A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen. <i>Experimental Hematology</i> , 2022, 111, 79-86.	0.2	2
5	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
6	Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. <i>British Journal of Haematology</i> , 2021, 192, 1064-1067.	1.2	6
7	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 192, 568-576.	1.2	19
8	Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study. <i>Annals of Hematology</i> , 2021, 100, 1079-1085.	0.8	4
9	Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study. <i>Annals of Hematology</i> , 2021, 100, 2061-2070.	0.8	7
10	Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy. <i>Targeted Oncology</i> , 2021, 16, 503-515.	1.7	9
11	Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 318-323.	1.1	5
12	Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. <i>Leukemia</i> , 2021, 35, 3534-3541.	3.3	71
13	Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. <i>British Journal of Haematology</i> , 2021, 192, 272-280.	1.2	15
14	A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, , 1-9.	0.6	3
15	Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 283-291.e1.	2.0	15
16	JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. <i>British Journal of Haematology</i> , 2020, 188, 283-294.	1.2	45
17	Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e492-e495.	0.2	3
18	Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e801-e804.	0.2	0

#	ARTICLE	IF	CITATIONS
19	A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2346-2353.	3.2	28
20	Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019, 14, 551-561.	1.7	10
21	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 570-578.e1.	0.2	20
22	Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. <i>Leukemia Research</i> , 2019, 81, 62-66.	0.4	36
23	A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e249-e250.	0.2	1
24	Normalization of Serum B-cell Maturation Antigen Levels Predicts Progression Free and Overall Survival in Multiple Myeloma Patients Starting Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e174.	0.2	1
25	The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. <i>Annals of Hematology</i> , 2019, 98, 691-703.	0.8	15
26	Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab. <i>Blood</i> , 2019, 134, 1853-1853.	0.6	1
27	Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments. <i>Blood</i> , 2019, 134, 1786-1786.	0.6	4
28	The role of JAK inhibitors in multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 500-505.	0.3	8
29	The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 319-329.	1.5	20
30	Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study. <i>European Journal of Haematology</i> , 2018, 100, 621-623.	1.1	4
31	Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 60-70.	1.2	9
32	The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma. <i>Targeted Oncology</i> , 2018, 13, 39-47.	1.7	30
33	Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e339-e343.	0.2	13
34	A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8005-8005.	0.8	4
35	Serum b-cell maturation antigen levels to predict progression free survival and responses among relapsed or refractory multiple myeloma patients treated on the phase I IRUX trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24313-e24313.	0.8	6
36	Circulating proteasomes: circling myeloma with a new potential biomarker. <i>Leukemia and Lymphoma</i> , 2017, 58, 513-515.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects. <i>Molecular Cancer Research</i> , 2017, 15, 598-609.	1.5	20
38	A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, 460-466.	2.0	13
39	Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. <i>Supportive Care in Cancer</i> , 2017, 25, 3217-3224.	1.0	2
40	Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. <i>Annals of Hematology</i> , 2017, 96, 441-448.	0.8	5
41	Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). <i>Leukemia Research</i> , 2017, 57, 45-54.	0.4	9
42	Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 785-795.	1.7	117
43	Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. <i>Annals of Hematology</i> , 2017, 96, 449-459.	0.8	22
44	Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e19-e20.	0.2	4
45	Monitoring multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 951-961.	0.3	10
46	Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. <i>British Journal of Haematology</i> , 2016, 174, 81-87.	1.2	18
47	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 127, 3360-3368.	0.6	89
48	Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. <i>European Journal of Haematology</i> , 2016, 97, 439-444.	1.1	11
49	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	49
50	Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 3383-3397.	3.2	74
51	Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. <i>Supportive Care in Cancer</i> , 2016, 24, 3105-10.	1.0	21
52	A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2015, 23, 1503-1512.	1.0	30
53	Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization. <i>Blood</i> , 2015, 126, 1011-1011.	0.6	1
54	Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenström's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels. <i>Blood</i> , 2015, 126, 1778-1778.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2931-2931.	0.6	1
56	a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 5383-5383.	0.6	4
57	Carfilzomib in multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1685-1699.	1.4	14
58	The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 197-210.	1.1	25
59	Management of bone disease in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 113-125.	1.0	86
60	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 89-98.	0.8	35
61	In vivo models of multiple myeloma (MM). <i>Biochemical Pharmacology</i> , 2014, 89, 313-320.	2.0	4
62	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014, 124, 1047-1055.	0.6	185
63	Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib. <i>Blood</i> , 2014, 124, 4106-4106.	0.6	7
64	Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 4713-4713.	0.6	1
65	Phase I trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013, 160, 321-330.	1.2	48
66	Novel In Vivo Models in Myeloma. , 2013, , 301-312.		0
67	Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. <i>Clinical Cancer Research</i> , 2012, 18, 3856-3867.	3.2	14
68	Multiple myeloma. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 330-336.	0.5	17
69	Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. <i>British Journal of Haematology</i> , 2012, 158, 727-738.	1.2	199
70	Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies. <i>European Spine Journal</i> , 2012, 21, 1826-1843.	1.0	200
71	The future of treatment for multiple myeloma. <i>Community Oncology</i> , 2012, 9, S47-S51.	0.2	0
72	CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. <i>Leukemia Research</i> , 2012, 36, 1422-1427.	0.4	24

#	ARTICLE	IF	CITATIONS
73	Is Vertebral Augmentation the Right Choice for Cancer Patients With Painful Vertebral Compression Fractures?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 715-719.	2.3	7
74	A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8098-8098.	0.8	3
75	Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. <i>Nature Reviews Endocrinology</i> , 2011, 7, 34-42.	4.3	103
76	A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 336-341.	0.2	2
77	Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial). <i>The Journal of Supportive Oncology</i> , 2011, 9, 32-40.	2.3	9
78	Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 225-235.	5.1	451
79	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 2011, 155, 580-587.	1.2	29
80	Using a Powered Bone Marrow Biopsy System Results in Shorter Procedures, Causes Less Residual Pain to Adult Patients, and Yields Larger Specimens. <i>Diagnostic Pathology</i> , 2011, 6, 23.	0.9	47
81	A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 193-200.	0.8	18
82	Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, S13-S23.	2.0	23
83	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. <i>American Journal of Hematology</i> , 2011, 86, 25-30.	2.0	19
84	The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. <i>Leukemia Research</i> , 2011, 35, 373-379.	0.4	45
85	Antitumor effects of bisphosphonates. <i>Current Opinion in Supportive and Palliative Care</i> , 2011, 5, 233-240.	0.5	25
86	Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011, 93, e106.	1.4	12
87	Therapeutic Options in the Management of Myeloma Bone Disease. <i>Seminars in Oncology</i> , 2010, 37, S20-S29.	0.8	8
88	Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. <i>European Journal of Haematology</i> , 2010, 84, 201-211.	1.1	50
89	The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. <i>British Journal of Haematology</i> , 2010, 148, 569-581.	1.2	70
90	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	1.2	95

#	ARTICLE	IF	CITATIONS
91	The Current Status and Future of Multiple Myeloma in the Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 28-43.	0.2	21
92	The Current Status and Future of Multiple Myeloma in the Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, E1-E16.	0.2	8
93	Bisphosphonates in the Treatment of Myeloma Bone Disease. , 2010, , 117-132.		0
94	A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 1069-1075.	3.2	40
95	Bortezomib in newly diagnosed multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 255-256.	12.5	7
96	Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. <i>European Journal of Haematology</i> , 2009, 82, 433-439.	1.1	21
97	Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 311-315.	1.4	9
98	Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. <i>Blood</i> , 2009, 113, 1992-2002.	0.6	82
99	A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 1855-1855.	0.6	9
100	Final Results of the First Randomized Trial Comparing Balloon Kyphoplasty (BKP) to Non-Surgical Management Among Cancer Patients with Vertebral Compression Fractures: Marked Improvement in Back Function, Quality of Life and Pain in the BKP Arm.. <i>Blood</i> , 2009, 114, 2873-2873.	0.6	4
101	Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. <i>Annals of Hematology</i> , 2008, 87, 623-631.	0.8	38
102	Animal Models of Multiple Myeloma and Their Utility in Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2008, 40, Unit 14.9.	4.0	16
103	Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss. <i>Clinical Cancer Research</i> , 2008, 14, 6289-6295.	3.2	67
104	New drugs in multiple myeloma. <i>Current Opinion in Supportive and Palliative Care</i> , 2008, 2, 204-210.	0.5	9
105	NF- κ B in the pathogenesis and treatment of multiple myeloma. <i>Current Opinion in Hematology</i> , 2008, 15, 391-399.	1.2	91
106	A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 1762-1768.	3.2	115
107	Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. <i>British Journal of Haematology</i> , 2007, 138, 467-478.	1.2	42
108	Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.. <i>Blood</i> , 2007, 110, 3602-3602.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 192-198.	1.4	50
110	Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2006, 24, 937-944.	0.8	205
111	Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. <i>British Journal of Haematology</i> , 2006, 135, 174-183.	1.2	74
112	Treatment strategies for skeletal complications of cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 1074-1077.	1.5	19
113	Pathophysiology of bone metastases. <i>Cancer Biology and Therapy</i> , 2006, 5, 1078-1081.	1.5	42
114	Bone complications in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2006, 5, 1082-1085.	1.5	18
115	Managing bone complications of solid tumors. <i>Cancer Biology and Therapy</i> , 2006, 5, 1086-1089.	1.5	26
116	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	0.8	587
117	Treatment for Myeloma Bone Disease: Table 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6279s-6284s.	3.2	41
118	LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. <i>International Journal of Oncology</i> , 2006, 28, 1409-17.	1.4	10
119	Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 2977-2981.	0.6	102
120	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , 2005, 104, 2141-2148.	2.0	99
121	Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases. <i>Oncologist</i> , 2005, 10, 52-62.	1.9	135
122	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	0.6	306
123	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results.. <i>Blood</i> , 2005, 106, 1565-1565.	0.6	102
124	A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2005, 106, 2565-2565.	0.6	3
125	Safety and Convenience of a 15â€¢Minute Infusion of Zoledronic Acid. <i>Oncologist</i> , 2004, 9, 319-329.	1.9	41
126	A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 130-134.	2.1	9

#	ARTICLE	IF	CITATIONS
127	Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan In Vitro and In Vivo.. Blood, 2004, 104, 2470-2470.	0.6	3
128	Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo.. Blood, 2004, 104, 2467-2467.	0.6	3
129	Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis. Journal of Clinical Oncology, 2003, 21, 4239-4247.	0.8	76
130	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 2003, 348, 2609-2617.	13.9	2,460
131	PS-341: prospecting a new hope for myeloma. Blood, 2003, 101, 1210-1210.	0.6	0
132	The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 2003, 9, 1136-44.	3.2	312
133	Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases. Journal of Clinical Pharmacology, 2002, 42, 1228-1236.	1.0	329
134	Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 2002, 99, 3163-3168.	0.6	228
135	Advances in the biology and treatment of myeloma bone disease. Seminars in Oncology, 2002, 29, 11-16.	0.8	27
136	Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in Oncology, 2002, 29, 12-18.	0.8	152
137	Advances in the biology and treatment of myeloma bone disease. American Journal of Health-System Pharmacy, 2001, 58, S16-S20.	0.5	6
138	Bone disease in myeloma. Current Treatment Options in Oncology, 2001, 2, 271-283.	1.3	13
139	A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 2001, 91, 144-154.	2.0	84
140	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001, 91, 1191-1200.	2.0	494
141	Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood, 2000, 95, 1869-1871.	0.6	53
142	American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 1378-1391.	0.8	355
143	Bisphosphonate Treatment of Lytic Bone Metastases. Drugs and Aging, 1999, 14, 241-246.	1.3	9
144	Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. Blood, 1997, 90, 1387-1394.	0.6	82

#	ARTICLE	IF	CITATIONS
145	Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. Blood, 1997, 90, 1387-1394.	0.6	7
146	Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. New England Journal of Medicine, 1996, 334, 488-493.	13.9	1,030